Mettler-Toledo International Inc. Q4 FY2025 earnings call

Financial Results

• Sales $1.1B, 8% USD growth; local currency +5% (4% ex-acquisitions).
• Gross margin 59.8%, down 140 bps; organic gross margin down 20 bps, impacted by tariffs.
• Adjusted EPS $13.36, up 8%; adjusted operating profit $363M, up 3%.

Product Innovations

• Launched Vero electronic pipette with long battery life and flow rate adjustment.
• Introduced X3 Series of X-ray solutions for Product Inspection.

Geographic Performance

• Americas: good growth across portfolio; Europe: better than expected due to Product Inspection; Asia/Rest of the World: good Q4 growth, China +3% led by industrial products.

Strategic Initiatives

• Focus on Spinnaker sales/marketing, automation, digitalization, onshoring; service business reached $1B in sales milestone.

Sales in the quarter were $1.1 billion, up 8% in U.S. dollar reported basis. Local currency sales increased 5% (4% excluding acquisitions). By region: Americas +7% (3% from acquisitions), Europe +4%, Asia/Rest of the World +4%, China +3%. By product: Laboratory +3%, Industrial +7% (3% from acquisitions, core Industrial +2% organic), Product Inspection +7% organic, Food Retail +19% in Q4, Service +8% (2% from acquisitions). Full year 2025: Local currency sales +3%, adjusted operating profit -1%, adjusted EPS +4%.

Full Year 2026

• Local currency sales growth unchanged at ~4% (ex-acquisitions).
• Operating margin expected up 60-70 bps (excluding currency); adjusted EPS $46.05-$46.70 (8%-9% growth).

First Quarter 2026

• Local currency sales growth ~3%; operating margin expected down ~100 bps (excluding unfavorable currency); adjusted EPS $8.60-$8.75 (5%-7% growth).

Other Guidance

• Total amortization ~$78M; interest expense ~$70M; other income ~$19M; free cash flow ~$900M; share repurchases $825M-$875M.

• Tariffs: Impact on gross margin and operating profit, with ongoing uncertainty.
• Geopolitical Tensions: Cautious customer investments at start of year, affecting growth.
• Market Volatility: Uncertainty in end markets like life sciences and biotech, impacting demand.

Q: Maybe on the 1Q commentary, Patrick, you talked about baking in that customers in spite of some positive headlines to your point on pharma and life sci customers, you're baking in a little more cautious to start the year. Is that something you're hearing through the first month and change here? Or is it just -- obviously, there's a typical Mettler conservatism. Just wondering if that's something you're picking up in the market or more just, hey, we don't want to bake in any improvement just yet. Let's see how it plays out. So it would be helpful to just talk through that 1Q guide.

A: Yes. Thanks, Patrick. And I'll let Shawn comment on this as well. But maybe to my comment on the headlines, again, headlines have been still pretty volatile. And while they have been better on the pharma and life sciences side, we all appreciate there's still more uncertainty in the market out there. And this also, across the broader portfolio and the broader markets we serve, still leads to longer deal cycles, et cetera. So as we said also in our Q3 call and also at the JPMorgan conference, we think our customers, and we feel that we'll start the year a bit more cautious, and we have really built that into our guidance for Q1 and for the full year.

Q: Congrats on the nice [ spin ]. Just back on the Q1 guidance, Shawn and Patrick. You guys did 4% organic in Q4. I think your Q1 is implying 2% organic, correct me if I'm wrong. What causes that 4% to 2% step down? And what are you assuming for end markets? When you say cautiousness, can you walk us through the different assumptions you're having industrial versus labs and pharma?

A: Yes, sure. So maybe I'll -- I can walk through maybe, Vijay, kind of like the assumptions for Q1 full year but also Q4. But as I kind of do it, you'll see that when we look at the beat, there was a very good beat on the Industrial side, especially Process Analytics. I mean, I'm sorry, not Process Analytics, Product Inspection. And then when you look at the geographies, you'll see Europe came in better than expected, also to a certain degree in the Americas. And as we were kind of entering the quarter, we were a little bit more concerned about Europe, but our Product Inspection business in Europe did particularly well. And then when we go through it, you'll also see that kind of what steps down a little bit from Q4 to Q1 just in terms of growth rates. You'll see that -- you'll see a little bit on the industrial side. You'll also see a little bit on the retail side. And then -- and also maybe this cautiousness in the Americas as well as to a certain degree in Europe.